CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
TM buprenorphine +1 moredrug
Likely dose
TM buprenorphine 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03993392
NCT03993392Phase 4Completed
CompareCT.gov

An Open-label, Rapid Initiation Study for Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE)

Indivior Inc.·interventional·Posted Jun 20, 2019·Updated Mar 25, 2025

In Brief

A Phase 4 clinical trial evaluating TM buprenorphine and SUBLOCADE for Opioid-use Disorder. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJun 20, 2019
Enrollment StartAug 29, 2019
Primary CompletionDec 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.0 years ago

Interventions

TM buprenorphinedrug

4mg TM buprenorphine, investigator choice as to brand

SUBLOCADEdrug

300mg subcutaneous injection